RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more
RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
RENAU.UNSP.ARD 1/5 EO-20 - Net Assets Trend (None–None)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RENAU.UNSP.ARD 1/5 EO-20 (None–None)
The table below shows the annual net assets of RENAU.UNSP.ARD 1/5 EO-20 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to RENAU.UNSP.ARD 1/5 EO-20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Market Cap
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jianglong Shipbuilding Co Ltd
SHE:300589
|
$455.60 Million |
|
Lancy Co Ltd
SHE:002612
|
$455.63 Million |
|
PT Unilever Indonesia Tbk
PINK:UNLRF
|
$455.68 Million |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
$455.95 Million |
|
Gogo Inc
NASDAQ:GOGO
|
$455.40 Million |
|
Fujian Septwolves Industry Co Ltd
SHE:002029
|
$455.31 Million |
|
CEVA Inc
NASDAQ:CEVA
|
$454.93 Million |
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
$454.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RENAU.UNSP.ARD 1/5 EO-20's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares RENAU.UNSP.ARD 1/5 EO-20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently RENAU.UNSP.ARD 1/5 EO-20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares RENAU.UNSP.ARD 1/5 EO-20's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $9,394,036,854
- Average return on equity (ROE) among peers: 4.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | €- | N/A | N/A | $455.45 Million |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $482.88 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $33.73 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $215.32 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $684.88 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $776.29 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.78 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.36 Billion |